Aug 2026· Cancers· Vol 18, pp. 2475· 0 citations· 37 references
Medicine
TL;DR
This study compares two open-source pathology foundation models—TITAN and CHIEF—for ER, PR, and HER2 prediction on the publicly available TCGA-BRCA cohort, under a strict patient-level evaluation protocol with 10 random partitions and 95% confidence intervals.
Abstract
Simple Summary Breast cancer treatment is guided by three molecular biomarkers—estrogen receptor (ER), progesterone receptor (PR), and HER2—typically measured by immunohistochemistry (IHC), a process that requires additional staining, time, and specialist review. Whole-slide image (WSI) foundation models are large pre-trained neural networks that summarize a digital biopsy into a compact representation, raising the possibility of inferring biomarker status directly from routinely stained H&E images. In this study, we compare two open-source pathology foundation models—TITAN and CHIEF—for ER, PR, and HER2 prediction on the publicly available TCGA-BRCA cohort, under a strict patient-level evaluation protocol with 10 random partitions and 95% confidence intervals. ER and PR predictions show robust discriminative performance under retrospective evaluation; HER2 prediction at the default decision threshold remains limited and motivates threshold-calibration and multimodal extensions. The findings are hypothesis-generating and motivate prospective external validation before any clinical use.
Prediction of breast cancer biomarkers from routine formalin-fixed, paraffin-embedded (FFPE) hematoxylin and eosin (H&E) images has been explored previously, but whether biomarker-associated morphologic signals can be reliably captured from artifact-prone intraoperative frozen-section (FS) specimens remains insufficien...
Shun Liu, Jun Li, Yi-Xiang Lian et al.· American Journal of Patholog...· 0 citations
Background Immunohistochemistry (IHC) remains the gold standard for assessing key breast cancer biomarkers such as estrogen receptor (ER) and progesterone receptor (PR). However, the staining process is resource-intensive, time-consuming, and dependent on specialized laboratory infrastructure. While recent advances in...
Hiba Alzoubi, Abdulla Shatarah, Abdulrhman Sanajleh et al.· Frontiers in Oncology· 0 citations
Accurate assessment of Human Epidermal Growth Factor Receptor 2 (HER2) amplification and Chromosome 17 (CEP17) copy number is critical for breast cancer treatment, yet diagnostically equivocal (IHC 2+) cases remain a clinical bottleneck. This study systematically benchmarks 14 feature encoders, including 12 Pathology...
Qing-Jie Lv, Xin Yu, Tao Wang et al.· npj Breast Cancer· 0 citations
Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure. This comprehensive pan-cancer study aims to develop a general, weakly supervised, and clinically interpretable deep learning (DL) approach for predictin...
Hao-Ran Xi, Xiao-Bing Feng, Ye Lu et al.· BMC Medical Imaging· 0 citations
Muscle-invasive bladder cancer (MIBC) exhibits significant heterogeneity in clinical outcomes and treatment responses. While gene expression profiling has provided important biological and prognostic insight, transcriptomic assays are not routinely incorporated into standard clinical practice, in part due to cost. AI m...
I. F. Mathisen, F. Koll, R. Mayer et al.· Modern Pathology· 0 citations
Overall, foundation models combined with weakly supervised learning provide competitive performance for BRAF status prediction in melanoma WSIs, but the findings highlight the need for diverse melanoma datasets and the importance of evaluating model performance beyond a single metric when developing H&E-based computati...
Lucy Godson, Jack Breen, Alexander I. Wright et al.· Frontiers in Medical Technol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.